[1]
Ferlay JS, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No 10. International Agency for Research on Cancer Lyon, France 2008.
[2]
Darefsky AS, Dubrow R. International variation in the incidence of adult primary malignant neoplasms of the brain and central nervous system. Cancer Causes Control 2009; 20(9): 1593-604.
[3]
SEER. Brain and other Nervous System in the United States, 2006-2010. SEER Cancer Statistic Review 2010.
[4]
McCarthy BJ, Schellinger KA, Propp JM, Kruchko C, Malmer B. A case for the worldwide collection of primary benign brain tumors. Neuroepidemiology 2009; 33(3): 268-75.
[5]
Registry HKC. Brain and Nervous System Tumours in Hong Kong 2013.
[6]
Ho-cheong H. Intracranial tumours among Chinese in Hong Kong. Surg Neurol 1979; 12(4): 317-8.
[7]
Ng HK, Poon WS, South JR, Lee JC. Tumours of the central nervous system in Chinese in Hong Kong: A histological review. Aust N Z J Surg 1988; 58(7): 573-8.
[8]
Chan G. Recent advances in childhood brain tumours. HK J Paediatr 2006; 11: 3-12.
[9]
Registry HKC. Brain and Nervous System Tumours in Hong Kong 2006.
[10]
Thomas DGT, Graham DI. The clinical study of gliomas. In: Brain Tumors: Scientific Basis, Clinical Investigation and Current Therapy. Johns Hopkins University Press USA 1980.
[11]
van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: Epidemiology, mechanisms, and management. Lancet Neurol 2007; 6(5): 421-30.
[12]
Kerkhof M, Dielemans JCM, van Breemen MS, Zwinkels H. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro-oncol 2013; 15(7): 961-7.
[13]
Laterra JBH. Diseases of the Nervous System: Clinical Neuroscience and Therapeutic Principles. 3rd ed. Primary brain tumours in adults. A.M. Asbury, I.; McKhann, G.; Goadsby, P.; McArthur, J. ed.; Cambridge University Press: UK,. 2002.
[14]
Stupp R, Mason WP, van den Bent M. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987-96.
[15]
Chan DT, Poon WS, Chan YL, Ng HK. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. Hong Kong Med J 2005; 11(6): 452-6.
[16]
Vredenburgh JJ, Desjardins A, Herndon 2nd JE. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25(30): 4722-9.
[17]
Friedman HS, Prados MD, Wen PY. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27(28): 4733-40.
[18]
Lacroix M, Abi-Said D, Fourney DR. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001; 95(2): 190-8.
[19]
Stummer W, Reulen HJ, Novotny A, Stepp H, Tonn JC. Fluorescence-guided resections of malignant gliomas--an overview. Acta Neurochir Suppl 2003; 88: 9-12.
[20]
Stummer W, Stepp H, Möller G, Ehrhardt A, Leonhard M, Reulen HJ. Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir (Wien) 1998; 140(10): 995-1000.
[21]
Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: A prospective study in 52 consecutive patients. J Neurosurg 2000; 93(6): 1003-13.
[22]
Nabavi A, Thurm H, Zountsas B. Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: A phase ii study. Neurosurgery 2009; 65(6): 1070-6. discussion 1076-7..
[23]
Widhalm G, Wolfsberger S, Minchev M. 5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer 2010; 116(6): 1545-52.
[24]
Roberts DW, Valdés PA, Paulsen KD. Adjuncts for maximizing resection: 5-aminolevuinic acid. Clin Neurosurg 2012; 59: 75-8.
[25]
Barbagallo GM, Paratore S, Caltabiano R. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: A single-institution experience with as many as 101 temozolomide cycles. Neurosurg Focus 2014; 37(6) E4
[26]
Seiz M, Krafft U, Freyschlag CF. Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: Experience of a single institution. J Cancer Res Clin Oncol 2010; 136(11): 1691-5.
[27]
Mannas JP, Lightner DD, Defrates SR, Pittman T, Villano JL. Long-term treatment with temozolomide in malignant glioma. J Clin Neurosci 2014; 21(1): 121-3.
[28]
Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. J Neurooncol 2012; 108(1): 173-7.
[29]
Hsieh SY, Chan DT, Kam MK. Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma. Hong Kong Med J 2017; 23(6): 594-8.
[30]
Blumenthal DT, Gorila T, Gilbert MK. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro-oncol 2017; 19(8): 1119-26.
[31]
Perry JR, Bélanger K, Mason WP. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 2010; 28(12): 2051-7.
[32]
Tsai CM, Au JS, Chang GC, Cheng AC, Zhou C, Wu YL. Safety and efficacy of first-line bevacizumab-based therapy in advanced non small cell lung cancer (NSCLC): results of the SAiL study (MO19390). J Thorac Oncol 2011; 6(6): 1092-7.
[33]
Reck M, von Pawel J, Zatloukal P. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27(8): 1227-34.
[34]
Wu JY, Wu XN, Ding L, et al. Phase I safety and pharmacokinetic study of bevacizumab in Chinese patients with advanced cancer. Chin Med J (Engl) 2010; 123(7): 901-6.
[35]
Pu JK, Chan RTT, Ng GKB, Leung GKK, Hung KN, Fung CF. Using bevacizumab in the fight against malignant glioma: First results in Asian patients. Hong Kong Med J 2011; 17(4): 274-9.
[36]
Wong ET, Hess KR, Gleason MJ. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17(8): 2572-8.
[37]
Patel M, Siddiqui F, Jin JY, et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: Radiographic response and improved survival. J Neurooncol 2009; 92(2): 185-91.
[38]
Hashmi A, Guckenberger M, Kersh R, et al. Re-irradiation stereotactic body radiotherapy for spinal metastases: A multi-institutional outcome analysis. J Neurosurg Spine 2016; 25(5): 646-53.
[39]
Jawad MS, Fahim DK, Gerszten PC, et al. on behalf of the Elekta Spine Radiosurgery Research Consortium. Vertebral compression fractures after stereotactic body radiation therapy: A large, multi-institutional, multinational evaluation. J Neurosurg Spine 2016; 24(6): 928-36.
[40]
Thibault I, Campbell M, Tseng CL, et al. Salvage Stereotactic Body Radiotherapy (SBRT) Following In-Field Failure of Initial SBRT for Spinal Metastases. Int J Radiat Oncol Biol Phys 2015; 93(2): 353-60.
[41]
Dahele M, Fehlings MG, Sahgal A. Stereotactic radiotherapy: an emerging treatment for spinal metastases. Can J Neurol Sci 2011; 38(2): 247-50.
6